PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1528066-0	1992	Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2"-deoxycoformycin.	Pentostatin	77-95	CD4 molecule	Homo sapiens	26-29	
8338781-3	1993	Within the PBL subsets, major changes concerned the CD4+ T cells, which during DCF therapy were distinctly suppressed to nadir values of 0.038-0.18 (median 0.126) x 10(9)/l.	Pentostatin	79-82	CD4 molecule	Homo sapiens	52-55	
1528066-1	1992	The leukemic cells of a patient with CD4+ prolymphocytic leukemia were treated in vitro with 5 microM deoxyadenosine and 60 microM 2"-deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA).	Pentostatin	131-149	CD4 molecule	Homo sapiens	37-40	
23632090-0	2013	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.	Pentostatin	30-41	CD4 molecule	Homo sapiens	18-21	
33423780-8	2021	It demonstrated the key role of CD4 Th1 specific responses of telomerase and M-MDSC as main prognostic factors for the therapeutic efficacy of DCF.	Pentostatin	143-146	CD4 molecule	Homo sapiens	32-35	
20001428-6	2010	Furthermore, the "gold standards" of HCL therapy - cladribine and pentostatin - are associated with profound and prolonged suppression of the CD4(+) T-lymphocyte counts, often in excess of 2 - 3 years.	Pentostatin	66-77	CD4 molecule	Homo sapiens	142-145	
10930997-6	2000	Accordingly, the combination of dCF (10-100 microM) plus dAdo was able to induce a dose-dependent inhibition of clonogenic growth and [3H]-thymidine incorporation in purified CD3+/CD4-/CD8- gammadelta+ tumour cells.	Pentostatin	32-35	CD4 molecule	Homo sapiens	180-183	
9001417-8	1997	After DCF, nadir CD4+ and CD8+ lymphocyte counts were significantly lower than prior to therapy (P < 0.0001 and P = 0.05, respectively), but returned to baseline levels during follow-up.	Pentostatin	6-9	CD4 molecule	Homo sapiens	17-20